Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4412 | Thrombin generation test assay Wiki | 0.45 |
| drug385 | Aspirin 81 mg Wiki | 0.45 |
| drug4413 | Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4411 | Thrombin Generation Assay (TGA) Wiki | 0.45 |
| drug3489 | Quantra System Wiki | 0.45 |
| drug1664 | Fibrin generation markers assays Wiki | 0.45 |
| drug3849 | Saline nasal and throat spray Wiki | 0.45 |
| drug392 | Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay Wiki | 0.45 |
| drug926 | Carrageenan nasal and throat spray Wiki | 0.45 |
| drug925 | Carotid Artery Reactivity Testing Wiki | 0.45 |
| drug945 | Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies Wiki | 0.45 |
| drug4692 | Vitamin D Wiki | 0.13 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004211 | Disseminated Intravascular Coagulation NIH | 1.00 |
| D020141 | Hemostatic Disorders NIH | 0.34 |
| D001778 | Blood Coagulation Disorders NIH | 0.34 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001928 | Abnormality of coagulation HPO | 0.34 |
| HP:0100512 | Low levels of vitamin D HPO | 0.14 |
Navigate: Correlations HPO
There are 5 clinical trials
Knowing the dramatic increase in thrombin generation during sepsis, our research hypothesis is that AMPK-induced ACC phosphorylation in platelets is increased and that this might modulate platelets metabolism and more particularly platelets inflammatory mediators content, coming from AA and lipids.
Description: ACC phosphorylation on Ser79 (phosphoACC) in platelets of patients will be assessed using western blotting. Results will be expressed in arbitrary units (A.U). A signal above 0.5 A.U. has already been shown to be above 2 standard deviation in a healthy population.
Measure: Platelets Acetyl-CoA Carboxylase phosphorylation rate Time: At the time of inclusionDescription: Sepsis severity will be assessed using the SOFA score (Sepsis-related Organ Failure Assessment). Range from 0( less severe) to 24 (more severe).
Measure: Sepsis severity Time: At the time of inclusionDescription: Sepsis severity will be assessed using the APACHE II score) Acute Physiology And Chronic Health Evaluation) Range 0 (less severe) to 299 (more severe).
Measure: Sepsis severity Time: At the time of inclusionDescription: Platelet function will be assessed using platelets aggregometry. The Aggregation (in AU), the maximum height of the curve during the measurement period will be assessed.
Measure: Platelet function assessment Time: At the time of inclusionDescription: Platelet function will be assessed using platelets aggregometry. Area Under the aggregation Curve (AUC) will be assessed and recorded as Units or U.
Measure: Platelet function assessment Time: At the time of inclusionDescription: Platelet function will be assessed using platelets aggregometry. Velocity (in AU/min), the maximum slope of the curve will be assessed.
Measure: Platelet function assessment Time: At the time of inclusionDescription: D-Dimers (ng/ml)
Measure: Thrombin generation marker rate Time: At the time of inclusionDescription: Urinary Thrombin-antithrombin complex (ng/mL)
Measure: Thrombin generation marker rate Time: At the time of inclusionDescription: Tubulin acetylation will be assessed using western blotting. Results will be expressed in arbitrary units (A.U).
Measure: Tubulin acetylation rate Time: At the time of inclusionDescription: Total platelets lipid content and composition will be assessed using metabolomics approach by Mass Spectrometry. Fold-change estimates and corresponding P values were derived from regression models for each lipid species and each predictor. To control for multiple testing, all P values will be further adjusted for Benjamini-Hochberg false discovery rate (FDR), with a FDR <0.05 considered statistically significant
Measure: Total platelets lipid content and composition Time: At the time of inclusionDescription: Myeloperoxidase MPO (ng/mL)
Measure: Neutrophils extracellular trap formation Time: At the time of inclusionDescription: Citrulinated Histon 3 H3-Cit (ng/mL)
Measure: Neutrophils extracellular trap formation Time: At the time of inclusionDescription: Soluble CD62P (ng/mL)
Measure: Platelets activation Time: At the time of inclusionDescription: PaO2/FiO2
Measure: Respiratory failure Time: At the time of inclusion and through study completion up to day 30Inflammation and abnormalities in laboratory coagulation tests are inseparably tied. For example, coagulation abnormalities are nearly universal in septic patients. Coagulation disorders have also been reported in many patients with severe courses of Coronavirus disease 2019 (Covid-19). But it is difficult to assess these changes. Global coagulation tests have been shown to incorrectly assess in vivo coagulation in patients admitted to intensive care units. But other tests are available. Thrombin generation assay (TGA) is a laboratory test which allows the assessment of an individual's potential to generate thrombin. But also in conventional TGA the protein C system is hardly activated because of the absence of endothelial cells (containing natural thrombomodulin) in the plasma sample. Therefore the investigators add recombinant human thrombomodulin to a conventional TGA. Thereby the investigators hope to be able to depict in vivo coagulation more closely than global coagulation tests do.
Description: nM;
Measure: ETP (AUC) without rhThrombomodulin (rhTM) Time: 6 monthsDescription: nM;
Measure: ETP (AUC) with rhThrombomodulin (rhTM) Time: 6 monthsDescription: Ratio of endogenous thrombin potential (ETP) with rhTM to ETP without rhTM
Measure: ETP-ratio Time: 6 monthsDescription: Comparison of ETP-ratios from ICU patients and ETP-ratios from citrated plasma samples from healthy donors
Measure: ETP-Normalisation Time: 6 monthsIncreased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death. Understanding this acquired coagulopathy is a prerequisite before specific interventional studies. The study investigators aim to apply a normalized and automated thrombin generation test (TGT), developed for testing the thrombotic risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to study its association with survival.
Description: Death yes/no during hopstilization, 28 days after admittence
Measure: 28-day survival rate Time: 1 monthDescription: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test latent period Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test latent period compared to reference plasma Time: Day 0Description: nmol/s; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test initial velocity Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test initial velocity compared to reference plasma Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin compared to reference plasma Time: Day 0Description: nmol/L; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin time compared to reference plasma Time: Day 0Description: seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test total thrombin generation time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test total thrombin generation time compared to reference plasma Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test endogenous thrombin potential Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test endogenous thrombin potential compared to reference plasma Time: Day 0Description: Death yes/no
Measure: 3-month survival rate Time: 3 monthsDescription: Yes/no
Measure: Transfer to intensive care unit during hospitalization Time: 3 monthsDescription: Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis)
Measure: Thrombotic complication during hospitalization Time: 3 monthsDescription: µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II)
Measure: Plasma concentrations of D-dimers Time: Day 0Description: mg / L, measured by automated immunoagglutination (STA®-Liatest® FM)
Measure: Plasma concentrations of soluble fibrin monomers Time: Day 0Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.
Description: Hospitalization for COVID-19 symptoms
Measure: Hospitalization Time: 2 weeksThis study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.
Description: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: Within 24 hours of admission to the hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: 48 to 72 hours after transfer to ICUDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: 1 to 24 hours prior to discharge from hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: Upon arrival at hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: 48 to 72 hours after transfer to ICUDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: 1 to 24 hours prior to discharge from hospitalAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports